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We identify amino acid variants within dominant SARS-CoV-2 T cell epitopes by
interrogating global sequence data. Several variants within nucleocapsid and
ORF3a epitopes have arisen independently in multiple lineages and result in
loss of recognition by epitope-specific T cells assessed by IFN-g and cytotoxic
killing assays. Complete loss of T cell responsiveness was seen due to Q213K in
the A*01:01-restricted CD8+ ORF3a epitope FTSDYYQLY207-215; due to P13L,
P13S, and P13T in the B*27:05-restricted CD8+ nucleocapsid epitope QRNAP-
RITF9-17; and due to T362I and P365S in the A*03:01/A*11:01-restricted CD8+
nucleocapsid epitope KTFPPTEPK361-369. CD8+ T cell lines unable to recognize
variant epitopes have diverse T cell receptor repertoires. These data demon-
strate the potential for T cell evasion and highlight the need for ongoing surveil-
lance for variants capable of escaping T cell as well as humoral immunity.
INTRODUCTION
Evolution of SARS-CoV-2 can lead to evasion from adaptive immunity generated following infection and
vaccination. Much focus has been on humoral immunity and spike protein mutations that impair the effec-
tiveness of neutralizing monoclonal antibodies and polyclonal sera. T cells specific to conserved proteins
play a significant protective role in respiratory viral infections such as influenza, particularly in broad heter-
osubtypic immunity (Hayward et al., 2015). T cell responses following SARS-CoV-2 infection are directed
against targets across the genome and may play a role in favorable outcomes during acute infection
and in immunosuppressed hosts with deficient B cell immunity (Huang et al., 2021; Peng et al., 2020; Tan
et al., 2021). Although CD8+ T cells may not provide sterilizing immunity, they can protect against severe
disease and limit risk of transmission, with a potentially more important role in the setting of antibody
escape.
Little is known about the potential for SARS-CoV-2 mutations to impact T cell recognition. Escape from an-
tigen-specific CD8+ T cells has been studied extensively in HIV-1 infection, where rapid intra-host evolution
renders T cell responses ineffective within weeks of acute infection (Goonetilleke et al., 2009). Although
these escape variants play an important role in the dynamics of chronic viral infections, the opportunities
for T cell escape in acute respiratory viral infections are fewer and consequences are different. Neverthe-
less, several cytotoxic T-lymphocyte (CTL) escape variants have been described in influenza, such as the
R384G substitution in the HLA B*08:01-restricted nucleoprotein380-388 and B*27:05-restricted nucleopro-
tein383-391 epitopes (Voeten et al., 2000). Long-term adaptation of influenza A/H3N2 has been demon-
strated, with the loss of one CTL epitope every 3 years since its emergence in 1968 (Woolthuis et al., 2016).
Medicine, University of
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Amino acid variants within experimentally proven SARS-CoV-2 T cell epitopes
To explore the potential for viral evasion from SARS-CoV-2-specific T cell responses, we conducted a proof-
of-concept study, focusing initially on identifying common amino acid mutations within experimentally
proven T cell epitopes and testing the functional implications in selected immunodominant epitopesiScience 24, 103353, November 19, 2021 ª 2021 The Author(s).
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Articlethat we and others have described previously. We conducted a literature review in PubMed and Scopus
databases (November 29, 2020; Data S4) that identified 14 publications defining 360 experimentally proven
CD4+ and CD8+ T cell epitopes (Chour et al., 2020; Ferretti et al., 2020; Gangaev et al., 2020; Habel et al.,
2020; Kared et al., 2021; Keller et al., 2020; Le Bert et al., 2020; Nelde et al., 2021; Peng et al., 2020; Poran
et al., 2020; Schulien et al., 2021; Sekine et al., 2020; Shomuradova et al., 2020; Snyder et al., 2020). Of these,
53 that were described in R1 publication were all CD8+ epitopes (Table S1) and distributed across the
genome (n = 14 open reading frame [ORF]1a, n = 5 ORF1b, n = 18 S, n = 2 M, n = 8 N, n = 5 ORF3a, n =
1 ORF7a). In total, 12,503 amino acid substitutions or deletions were identified within the 360 T cell epi-
topes by searching the mutation datasets downloaded from CoV-GLUE (http://cov-glue.cvr.gla.ac.uk/
#/home) on July 30, 2021 (Figure S1 and Table S2). A total of 1,370 amino acid variants were present within
the 53 CD8+ T cell epitopes with responses described acrossmultiple cohorts, with at least one variant in all
epitopes (Figure S2 and Table S3).
Functional impact of variants within immunodominant SARS-CoV-2 T cell epitopes
We focused on evaluating the functional impact of variants within seven immunodominant epitopes in
nucleocapsid, ORF3a, and spike (five CD8+, two CD4+) described in our study of UK convalescent donors
(Peng et al., 2020), along with a further immunodominant ORF1a CD8+ epitope described in several other
studies (Table 1). Of these, all six CD8+ epitopes have been described in at least two cohorts. In particular,
responses to the A*03:01/A*11:01-restricted nucleocapsid KTFPPTEPK361-369 (Ferretti et al., 2020; Gangaev
et al., 2020; Kared et al., 2021; Peng et al., 2020) epitope, A*01:01-restricted ORF3a FTSDYYQLY207-215 (Fer-
retti et al., 2020; Kared et al., 2021; Peng et al., 2020; Schulien et al., 2021) epitope, and A*01:01-restricted
ORF1a TTDPSFLGRY1637-1646 (Ferretti et al., 2020; Gangaev et al., 2020; Nelde et al., 2021) epitope are
consistently dominant and of high magnitude. We tested the functional avidity of SARS-CoV-2-specific
CD4+ and CD8+ polyclonal T cell lines by interferon (IFN)-g ELISpots using wild-type and variant peptide
titrations (Figures 1A–1F). We found that several variants resulted in complete loss of responsiveness to the
T cell lines evaluated: the Q213K variant in the A*01:01-restricted CD8+ ORF3a epitope FTSDYYQLY207-215
(Ferretti et al., 2020; Kared et al., 2021; Peng et al., 2020; Schulien et al., 2021); the P13L, P13S, and P13T
variants in the B*27:05-restricted CD8+ nucleocapsid epitope QRNAPRITF9-17 (Nelde et al., 2021; Peng
et al., 2020); and T362I and P365S variants in the A*03:01/A*11:01-restricted CD8+ nucleocapsid epitope
KTFPPTEPK361-369 (Ferretti et al., 2020; Gangaev et al., 2020; Kared et al., 2021; Peng et al., 2020) (Figures
1A–1C).
In contrast, Q9H in QRNAPRITF9-17, T366I in KTFPPTEPK361-369, P384L in the A*03:01-restricted CD8+ spike
epitope KCYGVSPTK378-386 (Ferretti et al., 2020; Peng et al., 2020), and M177I in the CD4+ spike epitope
CTFEYVSQPFLMDLE166-180 (Peng et al., 2020) showed no impact on T cell recognition (Figures 1B, 1C,
1F, and S3). In fact, T366I in KTFPPTEPK361-369 appeared to result in higher avidity (Figure 1C). Several other
variants showed partial loss of T cell responsiveness, with lower avidity observed to the variant peptide
compared with wild-type peptide. These included T325I in the B*40:01-restricted nucleocapsid epitope
MEVTPSGTWL322-331 (Nelde et al., 2021; Peng et al., 2020; Schulien et al., 2021), R765L in the
DRB1*15:01-restricted CD4+ spike epitope NLLLQYGSFCTQLNR751-765 (Peng et al., 2020), and L176F in
the CD4+ spike epitope CTFEYVSQPFLMDLE166-180 (Peng et al., 2020) (Figures 1D–1F). To confirm our find-
ings, we evaluated the impact of CD8+ T cell epitope variants on CTL killing of peptide-loaded autologous
B cells. Consistent with the ELISpot data, CTL killing ability was significantly impaired by Q213K in ORF3a
FTSDYYQLY207-215; P13L, P13S, and P13T in nucleocapsid QRNAPRITF9-17; and T362I and P365S in nucle-
ocapsid KTFPPTEPK361-369 (Figures 1G–1I). Partial impairment of killing ability was seen with T325I in
MEVTPSGTWL322-331 (Figure 1J). Several variants within the dominant A*01:01-restricted ORF1a epitope
TTDPSFLGRY1637-1646 (Ferretti et al., 2020; Gangaev et al., 2020; Nelde et al., 2021) also resulted in partial
loss of T cell recognition in both intra-cellular cytokine staining-based avidity assays (Figures 1K, 1L, 1M,
and S4) and a killing assay (Figures 1N and S4).
Potential mechanisms of loss of T cell recognition
T cell escape can occur via interrupting several mechanisms: antigen processing, binding of major histo-
compatibility complex (MHC) to peptide, or T cell receptor (TCR) recognition of the MHC-peptide com-
plex. Although we did not explicitly establish which of these was responsible in each case, it is likely that
any partial impairment of T cell recognition is due to reduced TCR binding to MHC-peptide. Reasons
for complete escape are more difficult to predict. As the anchor residues of peptide-MHC binding in
A*03:01/A*11:01-restricted KTFPPTEPK361-369 are at positions 2 and 9, T362I (position 2) may impair2 iScience 24, 103353, November 19, 2021
Table 1. Epitopes and variants studied
Epitope ORF CD4/CD8 HLA Variant Frequency (%) Countries
Global
lineages
Loss of T cell
response References describing epitope
FTSDYYQLY207-215 3a CD8 A*01:01 Q213K 0.059 56 95 Yes Ferretti et al. (2020); Kared et al., 2021; Peng
et al. (2020); Schulien et al. (2021),a
QRNAPRITF9-17 N CD8 B*27:05 Q9H 0.289 74 176 No Nelde et al. (2021); Peng et al. (2020)
QRNAPRITF9-17 P13L 0.978 97 194 Yes Nelde et al. (2021); Peng et al. (2020)
QRNAPRITF9-17 P13S 0.210 83 132 Yes Peng et al. (2020); Nelde et al. (2021)
QRNAPRITF9-17 P13T 0.102 45 81 Yes Nelde et al. (2021); Peng et al. (2020)
MEVTPSGTWL322-331 N CD8 B*40:01 T325I 0.069 52 109 Partial Nelde et al. (2021); Peng et al. (2020); Schulien
et al. (2021),b
KTFPPTEPK361-369 N CD8 A*03:01 A*11:01 T362I 0.293 85 165 Yes Ferretti et al. (2020); Gangaev et al. (2020)
,b;
Kared et al., 2021; Peng et al. (2020)
KTFPPTEPK361-369 T366I 0.237 74 154 No Ferretti et al. (2020); Gangaev et al. (2020)
,b;
Kared et al. (2021); Peng et al. (2020)
KTFPPTEPK361-369 P365S 0.794 73 142 Yes Ferretti et al. (2020); Gangaev et al. (2020)
,b;
Kared et al. (2021); Peng et al. (2020)
KCYGVSPTK378-386 S CD8 A*03:01 P384L 0.085 59 116 No Ferretti et al. (2020); Peng et al. (2020)
CTFEYVSQPFLMDLE166-180 S CD4 – L176F 0.260 68 158 No Peng et al. (2020)
CTFEYVSQPFLMDLE166-180 M177I 0.083 60 92 Partial Peng et al. (2020)
NLLLQYGSFCTQLNR751-765 S CD4 DRB1*15:01 R765L 0.017 31 64 Partial Peng et al. (2020)
0.000
TTDPSFLGRY1637-1646 ORF1A CD8 A*01:01 T1637I 0.189 58 113 Partial Ferretti et al. (2020); Gangaev et al. (2020),b;
Nelde et al. (2021)
TTDPSFLGRY1637-1646 T1638I 0.066 52 96 Partial Ferretti et al. (2020); Gangaev et al. (2020),b;
Nelde et al. (2021)
TTDPSFLGRY1637-1646 P1640S 0.202 69 165 Partial Ferretti et al. (2020); Gangaev et al. (2020),b;
Nelde et al. (2021)
TTDPSFLGRY1637-1646 P1640L 2.540 105 156 Partial Ferretti et al. (2020); Gangaev et al. (2020),b;
Nelde et al. (2021)
TTDPSFLGRY1637-1646 P1640H 0.050 27 20 Partial Ferretti et al. (2020); Gangaev et al. (2020),b;
Nelde et al. (2021)
Mutated positions detailed in red within wild-type epitope sequence. Frequency indicates % of sequences where variant is seen within the SARS-CoV-2 mutation dataset downloaded from CoV-GLUE (http://
cov-glue.cvr.gla.ac.uk/#/home) on July 30, 2021. Global Lineages refers to Pango lineage assignment.
ORF, open reading frame; HLA, human leukocyte antigen.
aResponses to longer peptide also seen in Snyder et al. (2020).
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Figure 1. Functional impact of mutations in key SARS-CoV-2 dominant epitopes
(A–F) Recognition of wild-type (black) and mutant (red) peptide titrations by polyclonal epitope-specific T cell lines in IFN-g ELISpot assays. SFU, spot
forming units. Shown are mean values from three or more replicates +/ standard deviation.
(G–J) Ability of CD8+ T cell lines to kill autologous B cells loaded with wild-type (black) or mutant (red) peptides in carboxyfluorescein succinimidyl ester
(CFSE) assays. The effector:target ratio denotes the proportion of CD8+ T cells:B cells in each assay.
(K–N) Recognition of wild-type (black) and mutant (red) peptide titrations by a polyclonal CD8+ T cell line specific for the HLA*A01:01-restricted ORF1a
epitope TTDPSFLGRY1637-1646, using intra-cellular cytokine staining for interferon-gamma (IFNg, K), tumor necrosis factor (TNFa, L), and the degranulation




Articlepeptide-MHC binding, while P365S (position 5) may affect a T cell binding residue (Rammensee et al.,
1999). The proline changes (P13L, P13S, P13T) in the B*27:05-restricted QRNAPRITF9-17 (position 5) again
may be at a key T cell contact residue, as peptide-MHC binding anchor residues are at positions 2 and 9
(Rammensee et al., 1999). The anchor residues for the A*01:01-restricted FTSDYYQLY207-215 are predicted




Articleexplain the impact of the Q213K (position 7) variant. In keeping with this, we see no significant impact of
these mutations on the predicted binding affinities of epitope to MHC (Table S4). Despite a modest
4-fold decrease in predicted IC50 for Q213K compared with wild type, FTSDYYKLY207-215 is still a strong
binder to A*01:01.
Ex vivo IFN-g ELISpots in two A*03:01 and two B*27:05 convalescent donors confirmed loss of responses to
variant peptides seen with T cell lines specific to KTFPPTEPK361-369 and QRNAPRITF9-17 (Figure S5). Thus,
our findings using T cell lines are representative of the circulating T cell response to these epitopes and of
physiological relevance. Of interest, one A*03:01 donor had low-level responses to P365S and T362I, sug-
gesting that subdominant responses via alternative TCR are possible.
T cell receptor diversity in CD8+ T cell lines with loss of epitope recognition due to amino acid
variants
TCR sequencing of polyclonal CD8+ T cell lines specific for the FTSDYYKLY207-215 epitope and B*27:05-
restricted QRNAPRITF9-17 epitope was undertaken to explore whether the complete loss of T cell recogni-
tion observed was dependent on specific TCRs. A diverse range of TCRs was found in FTSDYYKLY207-215
T cell lines from four donors (Figure 2), demonstrating that Q213K results in escape from several TCRs.
Similar findings were seen in TCR data from a B*27:05-restricted QRNAPRITF9-17 T cell line from one donor
(Figure S6). It is worth noting that our data are biased by using T cell lines generated from donors recruited
early in the pandemic and therefore likely infected with ‘‘wild-type’’ viruses (i.e., lineage B or B.1 viruses)
(Peng et al., 2020). Although variants that impair antigen processing or MHC-peptide binding result in irre-
versible loss of T cell recognition, CTLs with new TCR repertoires can overcome TCR-mediated escape var-
iants, as has been described in HIV-1 infection (Ladell et al., 2013).
Frequency of epitope variants over time and appearance in global SARS-CoV-2 phylogeny
Many variants examined in our study were at relatively low frequency and stable prevalence at the time of
writing, other than P365S in KTFPPTEPK361-369, P1640L in TTDPSFLGRY1637-1646, and variants affecting the pro-
line at position 13 in QRNAPRITF9-17 (Table 1 and Figure 3A). We explored whether variants that result in loss
of T cell recognition appeared as homoplasies in the phylogeny of SARS-CoV-2 suggestive of repeated inde-
pendent selection, or whether global frequency is due mainly to the expansion of lineages after initial acqui-
sition. Although in some cases variant frequency was dependent on a few successful lineages, P365S, Q213K,
T362I, P13L, P13S, and P13T had arisen independently on several occasions including within the B.1.1.7 line-
age (Figures 3B, 3C, 3D, 3E, S7A, and S7B). It is important to emphasize that this homoplasy and our functional
data do not prove selection due to T cell escape, which would require demonstration of intra-host evolution.
The positions we find important for T cell recognition may be under selective pressure for reasons other than
T cell immunity. A recent study has documented intra-host evolution of minority variants within A*02:01 and
B*40:01 CD8+ epitopes that impair T cell recognition, although not all epitopes are dominant and very few of
the variants studied were represented among the global circulating viruses (Agerer et al., 2021).
Conclusions
There is unlikely to be adequate population immunity at present to see global changes due to T cell selec-
tion akin to what has been seen in adaptation of H3N2 influenza over time (Woolthuis et al., 2016). Further-
more, polymorphism in HLA genes restricts the selective advantage of escape within one particular epitope
to a relatively small proportion of the population, given the breadth in T cell responses we and others have
shown. The polyclonal T cell response in a given individual is therefore unlikely to be diminished signifi-
cantly by mutations present in any one circulating variant, unlike the potential impact on neutralizing
antibody responses seen with mutations in the spike protein. Nevertheless, responses to many of the
CTL epitopes we have studied are dominant within HLA-matched individuals across many cohorts (Peng
et al., 2020). As A*03:01, A*11:01, and A*01:01 are common HLA alleles globally, loss of T cell responses
to dominant epitopes such as KTFPPTEPK361-369 and FTSDYYQLY207-215 may be significant. Substitution
of three different amino acid variants at nucleocapsid position 13 within the B*27:05-restricted QRNAP-
RITF9-17 epitope is also striking and suggests significant positive selective pressure at this site. Successful
maintenance of these substitutions within some lineages also suggest that this is a position where such
amino acid changes are tolerated with limited impact on the virus life cycle. A single dominant, protective
B*27:05-restricted epitope has been described in HIV-1 infection, with T cell escape associated with pro-
gression to AIDS. T cell escape from a B*27:05-restricted influenza A epitope (nucleoprotein383-391) has also





Figure 2. T cell receptor (TCR) repertoire of polyclonal CD8+ T cell lines specific for A*01:01-restricted ORF3a
epitope FTSDYYKLY207-215
(A, C, E, and G) Data are shown from T cell lines generated using peripheral blood mononuclear cells from four donors.
TheQ213K variant (red) showed complete loss of recognition in each case using peptide titrations in IFN-g ELISpot assays
compared with recognition of the wild-type (black) peptide. Shown are mean values from three or more replicates +/
standard deviation. SFU, spot forming units.
(B, D, F, and H) A diverse range of TCRs was observed.
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Figure 3. Global presence of variants in key dominant SARS-CoV-2 epitopes
(A) Weekly frequency over time since beginning of SARS-CoV-2 pandemic of all variants studied in functional
experiments. Mutation counts were obtained fromCOG-UK global metadata (dated August 4, 2021). Variants named with
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prefix of SARS-CoV-2 protein (S, spike; N, nucleocapsid), followed by wild-type amino acid, position within protein,
and variant amino acid. Epiweek relates to week number since start of global SARS-CoV-2 pandemic was declared on
March 11, 2020.
(B–E) Phylogenies representing global SARS-CoV-2 genomes depicting the presence of epitopes variants impacting
T cell responses. In each case, phylogenies represent all available variant sequences (red tips), along with a selection of
non-variant sequences, which were subsampled for visualization purposes. The bar to the right of each phylogeny is
annotated by main ancestral lineages only and not each individual PANGO lineage that viruses belong to. The grapevine
pipeline (https://github.com/COG-UK/grapevine) was used for generating the phylogeny based on all data available on




ArticleA significant increase in sites under diversifying positive selective pressure was observed around
November 2020, most notably in ORF3a, N, and S (Martin et al., 2021). As vaccine and naturally acquired
population immunity increase further, the frequency of variants we have described should be monitored
globally, as well as further changes arising within all immunodominant T cell epitopes. We have recently
incorporated the ability to identify spike T cell epitope variants in real-time sequence data into the
COG-UK mutation explorer dashboard (http://sars2.cvr.gla.ac.uk/cog-uk/). Non-spike T cell immune re-
sponses will also become increasingly important to vaccine-induced immunity as inactivated whole-virus
vaccines are rolled out. Our findings demonstrate the potential for T cell evasion and highlight the need
for ongoing surveillance for variants capable of escaping T cell as well as humoral immunity.Limitations of the study
Wehave chosen to focus on key SARS-CoV-2 immunodominant epitopes characterized early in the pandemic,
and further epitopes have been identified since. It would be important to assess mutations of increasing prev-
alence within all immunodominant epitopes in the future to provide a comprehensive overview of potential
SARS-CoV-2 T cell escape. Although our findings suggest that reduced T cell receptor binding to MHC-
epitope complex is likely responsible for the most striking impact of mutations on T cell responses we
describe, this needs to be demonstrated experimentally. Finally, further studies are required to demonstrate
the occurrence of T cell escape within individuals and establish how frequently this occurs. Given the potential
for immune escape in prolonged or chronic SARS-CoV-2 infections that could give rise to new variants of
concern, a focus on infections in immunocompromised individuals would be important.STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following:
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KEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
PE-Cy7 anti-human CD107a (H4A3) BD Biosciences, UK Cat#561348; RRID:AB_10644018
BV510 anti-human CD3 (UCHT1) BD Biosciences, UK Cat#563109; RRID:AB_2732053
BV421 anti-human CD8 (RPA-T8) BD Biosciences, UK Cat#562428; RRID:AB_11154035
PE anti-human TNFa (MAb11) Thermo Fisher Scientific Cat#12-7349-82; RRID:AB_466208
FITC anti-human IFNg (45-15) Miltenyi Biotec Ltd Cat# 130-091-641; RRID:AB_244194
FITC anti-human CD4 (SK3&SK4) BD Bioscience, UK Cat#347413; RRID:AB_400297
FITC anti-human CD8 (SK1) BD Bioscience, UK Cat#347313; RRID:AB_400279
BV421 anti-human CD19 (HIB19) Biolegend, UK Cat#302234; RRID: AB_10897802
Chemicals, peptides, and recombinant proteins
Synthesized peptides GenScript Biotech, Netherlands NA
QRNAPRITF-B*27:05 pentamer Proimmune Cat#4354
KTFPPTEPK-A*03:01 pentamer Proimmune Cat#4356A
MEVTPSGTWL-B*40:01 pentamer Proimmune Cat#4328
FTSDYYQLY-A*0101 pentamer Proimmune Cat#4355




IL-2/TCGF Helvetica healthcare Cat#0801017
IL-7 Biotechne, UK Cat#207-IL
Critical commercial assays
Human IFN-g ELISpot BASIC kit Mabtech Cat#3420-2A
SMARTer RACE 5’/30 kit TaKaRa Cat#634858
Monarch DNA gel extraction kit New England BioLabs Cat#T1020S
TOPO TA Cloning kit
for sequencing
Thermo Fisher Scientific Cat#K457501
RNeasy plus mini kit Qiagen Cat#74134
Advantage2 PCR kit TaKaRa Cat#639207
LIVE/DEAD fixable near-IR
dead cell stain kit
Thermo Fisher Scientific Cat#L34975
CellTrace CFSE cell proliferation kit Thermo Fisher Scientific Cat#C34554
CellTrace violet cell proliferation kit Thermo Fisher Scientific Cat#C34557
eBioscience 7-AAD viability
staining solution
Thermo Fisher Scientific Cat#00-6993-50
QIAprep spin miniprep kit Qiagen Cat#27106
Deposited data
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REAGENT or RESOURCE SOURCE IDENTIFIER
COG-UK metadata (original data is
unpublished and restricted by the data sharing
agreement with COG-UK, data provided in
supplementary information Tree_visualisation
(input_data) has been cleaned for the purpose
of public sharing and includes all publicly












Code for plotting global phylogenetic tree (In
supplementary information Tree_visualisation)
Custom NA
Experimental models: Cell lines
Lymphoblastoid cell lines (killing assay target
cells) – transformed with epstein-Barr virus and
ciclosporin A from healthy donors. Cell lines
like this are a standard reagent in many
laboratories. Cells are available upon request,
contingent upon material transfer agreement







Flowjo 10.7.1 BD Biosciences NA
NetMHCpan 4.1 Reynisson et al. (2020) http://www.cbs.dtu.dk/services/NetMHCpan/
R (version 3.5.3) R Core Team, 2021 https://www.r-project.org
GraphPad prism 9 GraphPad NA
Biorender Science Suite inc www.biorender.com
Other






Further information and requests for resources and reagents should be directed to and will be fulfilled by
the lead contact, Thushan de Silva (t.desilva@sheffield.ac.uk).Materials availability
This study did not generate new unique reagents.
Data and code availability
d Additional Supplemental Items are available fromMendeley Data at https://data.mendeley.com/datasets/
8gyvpj4wsc/draft?a=b1ce80de-e208-443e-a839-6b1852dafb63
d Code and data used for identifying mutations within T cell epitopes are provided in Data S1 Mutation




Articleand two sub-folders: input_data and output. Mutation datasets downloaded from CoV-GLUE are pro-
vided in the input_data sub-folder.
d Code and data used for plotting the variant prevalence over time are provided in Data S2 Variant prev-
alence, related to Figure 3. The analysis folder contains an R code and two sub-folders: input_data and
output.Mutation counts obtained from COG-UK global metadata are provided in the input_data folder.
d Code and data used for plotting the global phylogenies representation are provided in Data S3 Tree vis-
ualisation, related to Figure 3. The analysis folder contains an R code and two sub-folders: input_data
and output. COG-UK metadata and lists of sequences with our mutations of interest are provided in
the input_data sub-folder.
d Any additional information required to re-analyze the data reported in this paper is available from the
lead contact upon request.
The graphical abstract was created with Biorender.EXPERIMENTAL MODEL AND PARTICIPANT DETAILS
Participants
SARS-CoV-2 recovered donors were recruited in Oxford into the Sepsis Immunomics study (Ref 13/SC/
0296) and in Liverpool into the ISARIC study (Ref 13/SC/0149). Both studies were granted ethical approval
from the South Central - Oxford C Research Ethics Committee in England. The age and sex of donors used










Donor 10 M 46
Donor 11 F 58Isolation of peripheral blood mononuclear cells
Blood from participants was collected in EDTA anticoagulant tubes, layered onto an equal volume of lym-
phoprep (Stemcell) in a falcon tube at room temperature, then centrifuged at 800 3 g for 20 min at room
temperature with the brake off. Peripheral Blood Mononuclear Cells (PBMCs) were aspirated at the plas-
ma:lymphoprep interface and washed twice with RPMI medium.
Isolated PBMCs were cultured in RPMI (GIBCO) with 10% (v/v) fetal bovine serum (FBS), 100 units/mL peni-
cillin, 0.1 mg/mL streptomycin at 37C in 5% carbon dioxide (CO2) and used to generate polyclonal T cell
lines and lymphoblastoid cell lines.
Generation of polyclonal T cell lines
1–2 million PBMCs were seeded per well in a 24-well plate in RPMI (GIBCO) with 10% (v/v) human serum,
10% (v/v) IL-2/TCGF (Helvetica healthcare), 5 ng/mL IL-7 (Biotechne). Peptides were added at 10 ug/mL.
Cells were fed on day 4 or earlier if media the turned yellow and then every 4 days. On day 14, antigen-spe-
cific CD8+ T-cells were sorted with pentamer staining and CD4+ T-cells were sorted using tetramer stain-
ing. Subsequently, sorted cells were plated in a 96-well U-bottom plate with 100–1000 cells/well and fed




ArticleGeneration of lymphoblastoid cell lines
2–2.5 million PBMC were resuspended in 1 mL supernatant from B95-8 cells and added to 24 well plate,
then incubated 4–5 h at 37C in 5% CO2. Following incubation 1 mL of RPMI (GIBCO) with 20% (v/v)
FBS, 100 units/mL penicillin, 0.1 mg/mL streptomycin was added to each well and ciclosporin A (CSA)
added to a final concentration of 100 ng/mL. Cells were fed every 4–6 days and lines expanded when
required.Identification of amino acid variants within T cell epitopes
Variants within the 360 experimentally proven T cell epitopes were identified using mutation datasets
downloaded from CoV-GLUE (http://cov-glue.cvr.gla.ac.uk/#/home) on the 30th July 2021. Both amino
acid substitutions and deletions were considered in this study. Sequences were excluded if they did not
contain a start and/stop codon at the beginning and end of each ORF. COG-UK global metadata down-
loaded on 04th August 2021 was used to plot the variant over time (Figure 2A). Sequence positions
mentioned in this study are relative to Wuhan-Hu-1 (GenBank accession MN908947.3) and were compared
using custom R scripts (R version 3.5.3).Peptide titrations using T cell lines and IFN-g ELISpot assays
Polyclonal CD4+ and CD8+ T cell lines specific for seven previously described immunodominant epitopes
(Peng et al., 2020) were generated after MHC class I Pentamer or MHC class II tetramer sorting from
cultured short-term cultures of SARS-CoV-2 recovered donor PBMCs. Antigen-specific T-cells were
confirmed by corresponding Pentamer or tetramer staining. T-cells were stained with Live/Dead dye
(Thermo Fisher Scientific, UK), then stained with pentamer or tetramer, followed by CD8-FITC (BD Biosci-
ence, UK) or CD4-FITC (BD Bioscience, UK) staining. The functional avidity of T cell lines was assessed by
IFN-g ELISpot assays (Peng et al., 2015). T cell lines were stimulated with wild-type and variant peptide-
pulsed autologous B-cells, starting at 10 mg/mL and serial 1:5 dilutions using 400 cells T cells and 20,000
B cells per condition at 37C for 6 h. Peptides were synthesised by GenScript Biotech (Netherlands) B.V.
To quantify antigen-specific responses, spots of the control wells, containing no peptide, were subtracted
from test wells and results expressed as spot forming units (SFU) per 400 T-cells. If negative control wells
had >30 SFU/T-cells or positive control (PHA) were negative, results were considered invalid. Duplicate
wells were used for each test and results are from three to seven independent experiments.Ex vivo IFN-g ELISpots in SARS-CoV-2 recovered donors
Cryopreserved PBMCs were used from SARS-CoV-2 recovered donors for ex vivo IFN-g ELISpots with wild-
type and variant peptides. Peptides were added to 200,000 PBMCs at a final concentration of 2 mg/mL for
16–18 h (two replicates per condition). Results were interpreted as detailed above. PBMCs used were from
samples taken when patients were between 35 and 53 days from symptom onset.Peptide titrations using T cell lines and intra-cellular cytokine staining
The functional avidity of polyclonal CD8+ T cell lines specific for the ORF1a epitope TTDPSFLGRY1637-1646
(Ferretti et al., 2020; Gangaev et al., 2020; Nelde et al., 2021) was assessed using stimulation with wild-type
and variant peptides starting at 1000 nM and serial 1:10 dilutions, followed by intra-cellular cytokine stain-
ing (ICS). 1–1.5 3 106 cells were plated in R10 in a 96 well U-bottom plate and peptide added. DMSO was
used as the negative control at the equivalent concentration to the peptides. Degranulation of T cells (a
functional marker of cytotoxicity) was measured by the addition of an anti-CD107a-PE-Cy7 antibody (clone
H4A3, BD Biosciences, UK) at 1 in 20 dilution during the culture. The cells were then incubated at 37C, 5%
CO2 for 1 h before adding Brefeldin A (10 mg/mL). Samples were incubated at 37
C, 5% CO2 for a further 5 h
before proceeding with staining for flow cytometry. Cells were stainedwith a cell viability dye (near infrared,
Thermo Fisher Scientific, UK) at 1:500 then fixed in 2% formaldehyde for 20 min, followed by permeabiliza-
tion with 13 Perm/Wash buffer (BD Biosciences). Staining was performed with the following antibodies:
anti-CD3-BV510 (clone UCHT1, BD Biosciences), anti-CD8-BV421 (clone RPA-T8, BD), TNF-PE (clone
MAb11, Thermo Fisher Scientific) and anti-IFN-g-FITC (clone 45-15, Miltenyi Biotec Ltd, UK). Samples
were run on a FacsCanto II cytometer and the data were analyzed using FlowJo software version 10 (BD
Biosciences). During analysis, exclusion of doublet cells was performed, followed by gating on live periph-
eral blood mononuclear cells and estimation of the % of CD3+CD8+ T-cells expressing cytokines at each




ArticleCytotoxic T-lymphocyte (CTL) killing assays
Killing assays were performed in one of two ways. (1) For T cell lines characterised using IFN-g ELISpot as-
says, autologous B-cells were stained with 0.5 mmol/L carboxyfluoroscein succinimidyl ester (CFSE, Thermo
Fisher Scientific) beforewild-typeor variant peptide loading at 1mg/mL for one hour. Peptide-loadedB-cells
were co-cultured with CTLs at a range of effector:target (E:T) ratios from 1:4 to 8:1 at 37C for 6 h and cells
stained with 7-AAD (eBioscience, UK) and CD19-BV421 (clone HIB19, Biolegend, UK). Assessment of cell
death in each condition was based on the CFSE/7-AAD population present. (2) For the ORF1a epitope
TTDPSFLGRY1637-1646 (Ferretti et al., 2020; Gangaev et al., 2020; Nelde et al., 2021) characterised using
ICS, appropriately HLA-matched peptide-loaded B-cells were used as target cells and labeled with CFSE
according to the manufacturer’s protocol. Briefly, cells were pulsed with varying concentrations of peptide
(1000 nM followed by 1:10 serial dilutions) for one hour at 37C. Unpulsed cells were labeled with Cell Trace
violet (CTV;Molecular Probes). Pulsed andunpulsed cells weremixed in a 1:1 ratio and 50 ul added to 50 ul of
peptide-specific short-term T cell lines and incubated in a 96 well plate for 10 h at an effector/target ratio
of 10:1 in duplicates. After incubation, cells were stained with near IR viability marker, CD3 (clone UCHT1;
eBioscience), CD8 (clone RPA-T8; eBioscience), and CD19 (clone LT19; Mitenyi Biotec). The mean percent
survival of CFSE-labelled cells in wells containing no effector cells was used to calculate the expected fre-
quency of target cells in eachwell: expected ratio (ER) was calculated as%CFSE+/%CTV+. The specific killing
was then calculated as: % Specific killing = 11 3 [(ER x %CTV+ cells) - %CFSE + cells]/(ER x %CTV+ cells).Predictions of binding strength of peptides to MHC
NetMHCpan 4.1 (http://www.cbs.dtu.dk/services/NetMHCpan/, Reynisson et al., 2020) was used to predict
the binding strength of wild type and variant epitopes under standard settings (strong binder % rank 0.5,
weak binder % rank 2). The predicted affinity (IC50 nM) for variant epitopes was compared with wild type.T cell receptor (TCR) sequencing
One million cells from each epitope-specific polyclonal CD8+ T-cell line were harvested and washed three
times with Phosphate Buffered Saline. Total RNA was extracted using the RNeasy Plus Mini kit (Qiagen,
Germany), and cDNAwas then synthesized from 300 ng RNA using the SMARTer RACE cDNA amplification
kit (Takara Bio, Japan) following the manufacturer’s instruction. Subsequently, cDNA was amplified for var-
iable regions of the TCR-b chain using the PCR Advantage kit (Takara Bio), with the primer 50-TGCT
TCTGATGGCTCAAACACAGCGACCT-30 and run on a 1.2% agarose gel for PCR band confirmation (at
500 bp). PCR products were purified using the Monarch DNA Gel Extraction kit (New England BioLabs,
USA) and then transformed into TOP10 competent cells (ThermoFisher). Plasmid DNA was extract using
the Spin Miniprep kit (Qiagen) followed by Sanger sequencing.Phylogenetic tree generation
Phylogenies were generated using the grapevine pipeline (https://github.com/COG-UK/grapevine) based
on all data available on GISAID and COG-UK up until 8th August 2021. To visualise all sequences with a spe-
cific amino acid variant of interest in a global context, a representative sample of global sequences was
obtained in two steps. First, one sequence per country per epi week was selected randomly, followed by
random sampling of the remaining sequences to generate a sample of 6000 down-sampled sequences.
The global tree was then pruned using code adapted from the tree-manip package (https://github.com/
josephhughes/tree-manip).
The tips of sequences with amino acid variants impacting T cell recognition were colour-coded. Visualisa-
tions were produced using R/ape, R/ggplot2, R/ggtree, R/treeio, R/phangorn, R/stringr, R/dplyr, R/aplot.QUANTIFICATION AND STATISTICAL ANALYSIS
Mean and standard deviation for replicates used in T cell experiments were calculated and plotted using
GraphPad Prism version 9. No quantitative statistical analysis was undertaken in this manuscript.iScience 24, 103353, November 19, 2021 15
